Kyverna Therapeutics Taps Ironwood CFO Greg Martini as Financial Lead Amid Commercial Push
Event summary
- Greg Martini joins Kyverna Therapeutics as CFO on May 18, 2026, succeeding Dr. Marc Grasso.
- Martini brings commercial-stage experience from Ironwood Pharmaceuticals, where he led financial strategy and investor relations.
- Kyverna grants Martini an option to purchase 325,000 shares, vesting over four years.
- Martini will oversee financial strategy as Kyverna advances miv-cel (KYV-101) toward potential approval in stiff person syndrome.
The big picture
Kyverna’s appointment of Martini underscores its shift toward commercialization, a critical phase for biopharmaceutical companies developing cell therapies. Martini’s background in financial strategy and commercial-stage growth is particularly relevant as Kyverna prepares for potential approval and launch of miv-cel. The move reflects broader industry trends where financial leadership with commercial experience is prioritized to navigate the complexities of bringing innovative therapies to market.
What we're watching
- Commercialization Timing
- How quickly Kyverna can transition to a commercial-stage organization and secure regulatory approval for miv-cel.
- Financial Strategy
- Whether Martini’s experience in capital allocation and investor relations can drive long-term value creation.
- Pipeline Expansion
- The pace at which Kyverna advances miv-cel into additional indications like generalized myasthenia gravis.